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Background: The Valsartan Antihypertensive Long-
term Use Evaluation (VALUE) study compares cardiovascu-
lar outcomes in 15,314 eligible patients from 31 countries
randomized to valsartan or amlodipine-based treatment.
Methods: The blood pressure (BP) trends are analyzed
in 13,449 of VALUE study patients who had baseline BP
and 24 months BP and treatment data.
Results: In a cohort of 12,570 patients, baseline 24 and 30
months BP, but not 30 months treatment data, were available.
Of 13,449 patients, 92% (N  12,398) received antihyper-
tensive therapy at baseline. The baseline BP was 153.5/86.9
mm Hg in treated compared to 168.1.8/95.3 mm Hg in 1051
untreated patients. After 6 months both groups had indistin-
guishable BP values. At 12 months the BP decreased to
141.2/82.9 mm Hg (P  .0001 for systolic BP and diastolic
BP versus baseline), at 24 months to 139.1/80 mm Hg (P 
.0001 v 12 months), and to 138/79 mm Hg at 30 months (P
 .0001 v 24 months). The systolic BP control (140 mm
Hg) at 30 months increased from 21.9% at baseline to 62.2%,
the diastolic BP ( 90 mm Hg) from 54.2% to 90.2% and the
combined control (140 and 90 mm Hg) from 18.9% to
60.5%. At 24 months 85.8% of patients were on protocol
drugs: monotherapy  39.7%, added hydrochlorothiazide 
26.6%, add-on drugs  15.1%, and protocol drugs in non-
standard doses  4.3%.
Conclusions: The achieved BP control exceeds values
reported in most published large-scale trials. The VALUE
study is executed in regular clinical settings and 92% of
the patients received antihypertensive drugs at baseline.
When an explicit BP goal is set, and a treatment algorithm
is provided, the physicians can achieve better control rates
than in their regular practice. Am J Hypertens 2003;16:
544–548 © 2003 American Journal of Hypertension, Ltd.
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T he Valsartan Antihypertensive Long-term Use Eval-uation (VALUE) study is one of the largest ongoingtrials investigating whether various antihypertensive
agents might have different effects on cardiovascular out-
comes. Such trials are based on the concept that blood pres-
sure (BP) elevation is only one, albeit the most visible, sign
of multiple pathophysiologic abnormalities in the syndrome
of hypertension. Many of these abnormalities might indepen-
dently cause damage to the cardiovascular (CV) system.
When properly dosed, most antihypertensive agents decrease
BP to the same extent but often have divergent effects on
vascular function, coagulation, and associated metabolic,
neurohumoral, and hemodynamic correlates of hypertension.
Specifically, the VALUE study investigates whether lower-
ing BP with the angiotensin receptor blocking agent valsartan
(Diovan; Novartis, Basel, Switzerland), which antagonizes
multiple negative effects of angiotensin, would yield better
CV outcomes than treatment with the calcium antagonist
amlodipine (Norvasc; Pfizer, New York, NY). The trial hy-
pothesis states that for the same level of BP control valsartan-
Received January 16, 2003. First decision February 27, 2003. Accepted
March 20, 2003.
From the Department of Internal Medicine (SJ), Division of Hyper-
tension, University of Michigan Health System, Ann Arbor, Michigan;
Division of Cardiology (SEK), Ullevaal University Hospital, Oslo,
Norway; Hypertension Division (HB), University of Lausanne, Lau-
sanne, Switzerland; Department of Geriatrics (LH), University of Upp-
sala, Uppsala, Sweden; Cardiovascular Clinical Research (FP, SE),
Novartis Pharma AG, Basel, Switzerland; Hypertension and Cardiovas-
cular Center (JHL), New York Presbyterian Hospital-Weill Medical
College, New York, New York; Department of Medicine and Ther-
apeutics (GM), University of Glasgow, Glasgow, United Kingdom;
Department of Medicine (MW), SUNY Downstate College of Medicine,
New York, New York; Department of Biostatistics (AMS), University
of Michigan School of Public Health, Ann Arbor, Michigan; Cardio-
vascular Clinical Research (BS), Novartis Pharmaceuticals Corpor-
ation, East Hanover, New Jersey; Centro di Fisiologia Clinica e Iperten-
sione (AZ), University of Milan, Instituto Auxologico Italiano, Milan,
Italy.
Address correspondence and reprint requests to Professor Stevo
Julius, University of Michigan Health System, Department of Internal
Medicine, Division of Hypertension, 3918 Taubman Center, Ann Arbor,
MI 48109-0356; e-mail: sjulius@umich.edu
AJH 2003; 16:544–548
0895-7061/03/$30.00 © 2003 by the American Journal of Hypertension, Ltd.
doi:10.1016/S0895-7061(03)00904-X Published by Elsevier Inc.
based treatment would be superior to amlodipine-based
treatment in reduction of cardiac morbidity and mortality
among hypertensive patients with a high CV risk.1
Methods
The rationale and design of the VALUE trial, including
outcome measures, statistical methods and baseline charac-
teristics of patients, CV risk profile, and definition of events
have been published in detail elsewhere.1,2 Patients of both
genders with hypertension, 50 years of age or older were
included. Previously untreated patients had to have a mean
sitting systolic BP (SBP) of 160 to 210 mm Hg and a
diastolic BP (DBP) of 95 to115 mm Hg. No lower BP limit
was set for patients already receiving antihypertensive treat-
ment, but the upper safety limit was set at210/115 mm Hg.
In addition to qualifying BP criteria the investigators used a
specific predefined age-risk factor-dependent algorithm to
recruit high CV risk patients into the study.1
The VALUE study is a multicenter, double-blind, ran-
domized, prospective, active-controlled parallel group trial of
the effect of two treatment modalities on BP and on CV end
points in hypertension. An angiotensin receptor blocking
agent, valsartan, in doses of 80 or 160 mg/day is compared to
a calcium antagonist, amlodipine, in doses of 5 or 10 mg/day
(steps 1 and 2). Additional treatment may be given as open
label hydrochlorothiazide, 12.5 or 25 mg (steps 3 and 4).
Initial dose adjustments were made in monthly intervals. If
needed, added antihypertensive medication except other an-
giotensin I receptor blockers, angiotensin converting enzyme
inhibitors, or calcium antagonists may be added (step 5) to
reach a target BP of 140/90 mm Hg (Fig. 1).
Patients were randomized to one of the treatment regi-
mens and will be followed for 4 to 6 years or until 1450
patients have experienced a primary event.1 This study is end
point-driven and it has been calculated that 14,400 enrolled
patients are needed to detect a 15% between-group difference
in CV outcomes with a 90% power and a significance of P
.05 during an average of 5 years of treatment. When the
enrollment into the study was closed, a large number of
patients had already given written informed consent and
eventually 914 more patients than planned were included. All
patients read and signed informed consents approved by
appropriate Local Institutional Review Boards.
Differences between groups were analyzed by a Wil-
coxon’s two-sample test or, when appropriate, by a two-
tailed Fisher’s exact test.
Results
Although 15,314 eligible patients in 30 countries were ran-
domized by December 31, 1999, this paper reports on 13,449
patients who 1) had complete BP records at baseline; 2) had
in-study BP at each point up to 24 months; and 3) had
information about the treatment status at 24 months. In ad-
dition we summarize 30 months of BP status for those 12,570
patients whose records presently contain baseline, 24, and 30
months BP data but their treatment status at 30 months BP
data had not yet been entered into the records. Consequently,
we report on BP trends and achievement of BP control after
24 and 30 months but analyze the utilization of blinded drugs
only after 24 months of treatment.
From the total of 15,314 original patients, 1864 were
excluded from the 24-month report as a result of death (N
 524), discontinuation for other reasons than death (N 
1012), and nonavailability of 24 months reports (N 
328). Among the patients with 30 months of data there
were 2744 fewer subjects than originally randomized for
the following reasons: deaths (N  529), discontinuation
for other reasons than death (N  1080), and nonavail-
ability of 30 months reports (N  1135). The apparent
small increase of deaths from 24 to 30 months most likely
reflects the degree of completeness of the 30-month data
set at time of writing of this paper. As indicated earlier the
data set contained BP data only. It is likely that this
number will increase when 1135 patients in whom 30
months of data were not available are accounted for and
when a fully completed data set becomes available.
The SBP Initiative
We took note of the fact that the BP changed very little
from the sixth month (when the initial medication up-
titration could be completed) to 12 months. A large num-
ber of patients at that point had uncontrolled SBP.
Consequently, we mounted a concentrated effort to im-
prove SBP control. In addition to discussion of the prob-
lem at investigator meeting and communications with
newsletters, we informed each investigator about specific
patients who had uncontrolled SBP in their clinic. There-
after, throughout the duration of the study, with the help of
physicians in charge of each country (national coordina-
tors), we closely monitored the BP trends.
BP Trends in the Study
Fig. 2 illustrates the BP trends in the cohort of 13,499
patients that had 24 months of BP data. The broken line at
the end of the graph illustrates the BP trend in 12,570
patients who had BP recordings at 24 and 30 months. A
majority of 13,499 patients with 24 months of BP data (n
FIG. 1. Valsartan Antihypertensive Long-term Use Evaluation
study design. A  amlodipine; HCTZ  hydrochlorothiazide; V 
valsartan.
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 12,398, 92.2%) received antihypertensive drugs before
enrollment and were “rolled over” to study drugs (circles).
The baseline BP of the 1051 patients who were not re-
ceiving treatment before enrollment (triangles) was 14.6/
8.4 mm Hg higher than in the previously treated patients.
However, both the treated and untreated groups achieved
similar BP levels already at 4 months and past the sixth
month point the BP readings of both groups were identical.
The BP changed very little between 4 and 12 months, but
after initiation of the SBP initiative (see Methods) the BP
of the entire population started to decrease. The readings
(SBP/DBP) at 24 months were 1.3/1.0 mm Hg lower than
at 12 months (P  .0001/.0001) and at 30 months 1.0/1.0
mm Hg lower than at 24 months (P  .0001/.0001).
BP Control and Drug Utilization
Blood pressure control at baseline, after 6 months (when
the initial medication up-titration should have been com-
pleted), and semiannually thereafter (Fig. 3). At baseline
21.9% of patients had SBP 140 mm Hg, at 24 months
the SBP control increased to 59.5%, and at 30 months to
62.2%. The DBP control increased from 54.2% to 88.6%
and 90.2%, respectively. Combined SBP and DBP control
at 30 months was 60.5%. As Fig. 3 shows the better rates
of BP control were mirrored by the drug utilization: The
percentage of patients on lowest dose of monotherapy
decreased, whereas the utilization of the highest step of
titration (step 5) increased.
The degree of BP control at 30 months is shown in Fig.
4. Whereas 62.2% of patients had controlled SBP, an
additional 20.6% had “nearly controlled” (140 to 150
mm Hg) SBP readings, 9.3% had “inadequate” SBP con-
trol (150 to 160 mm Hg), and 7.9% had “uncon-
trolled” systolic hypertension (160 mm Hg). In parallel
the DBP control at 30 months (90 mm Hg) was 90.2%,
an additional 6.5%, had “near control” values (90 to
FIG. 2. Blood pressure (BP) trends in the cohort of 13,449 patients who had baseline and 24 months of data (dots) and in 12,750 patients
who also have 30 months of data (broken line). Triangles denote the pressures in 1051 patients who were not receiving antihypertensive
treatment before the enrollment.
FIG. 3. Blood pressure control rates (percentage 140 or 90 mm
Hg) from baseline to 30 months. Up to 24 months N  13,449; at 30
months, N  12,570. The line shows the percentage of combined
(systolic and diastolic) blood pressure control. The percentage uti-
lization of the lowest dose of monotherapy and of the highest titra-
tion step (step 5) from 6 to 24 months is shown under the figure.
FIG. 4. Distribution of degrees of blood pressure control at 30
months (N  12,750).
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95 mm Hg), “inadequate” readings (95 to 100 mm
Hg) were present in 2%, and “uncontrolled” DBP (100
mm Hg) was seen in 1.3% of patients.
The relationship of treatment status to BP control at 24
months is illustrated in Fig. 5. Here the percentage of patients
on a given treatment step is given in bold letters and the
percentage of BP control is given in italics. After 2 years in
the study, 66.3% of patients received active monotherapy or
addition of a diuretic. In another 15.1% other antihyperten-
sive drugs permitted by the protocol were added. In an
additional 4.3% of patients the physicians prescribed drugs
defined by the protocol but in different doses than stipulated
(for example, diuretic added already to the first step of
monotherapy, or one treatment component down-titrated
from a protocol step). Thus, a total of 81.4% of patients
adhered to the study protocol and 85.8% received drugs
investigated in the VALUE study. The remaining 18.5%
patients were followed in our clinics but did not receive per
protocol treatment. Among them 6.3% received added drugs
not foreseen by the protocol, 3.7% were not taking the study
drug at 24 months (“temporary discontinuation”), 8.3% per-
manently discontinued study drugs, and in 0.3% information
was missing.
Fig. 5 also shows that at 24 months 39.7% of patients
still received monotherapy and among them almost 30%
had uncontrolled BP levels but additional steps of the
protocol were not used. At 24 months 23.9% of patients
received only the first step of monotherapy. In this group
the BP was not at goal in 25% but they were not further
up-titrated. Similarly, in the diuretics-added group the BP
was not at goal in approximately 44% of patients but the
fifth step of the protocol had not been used.
Discussion
The baseline status of 12,398 patients who received anti-
hypertensive treatment before enrollment in the VALUE
study gives an insight on how hypertension is treated in
routine clinical practice. Among patients treated for high
BP at the entry into the study, the baseline SBP was
controlled (140 mm Hg) only in 21.9% subjects com-
pared to a 54.2% control rate (90 mm Hg) of the DBP.
These findings confirm other observations that practicing
physicians are more successful in controlling the DBP
than SBP.3–9 After 24 months in the study the control rates
increased to 59.3% for SBP and 88.5% for DBP. A further
improvement in SBP control to 62.2% and of DBP to
90.2% has been noticed in patients who completed the 30
months examination (Fig. 3). Because the VALUE study
is executed in regular clinical settings the results demon-
strate that physicians can achieve much better control rates
when they work in a structured environment, which sets
explicit BP goals, provides a simple algorithm to achieve
these goals, and educates the patient and the personnel
alike about the importance of achieving a good BP control.
Despite considerable improvement of BP management
in the VALUE study our 24 and 30 months of BP outcome
is still not ideal. However, the results reported herein are
substantially better than in most published studies. The
average achieved SBP level in VALUE is 16 mm Hg
lower than in the Stroke Prevention Trial 2 (STOP-2)10
and Nordic Diltiazem (NORDIL)11 studies, 12 mm Hg
below the value in Systolic Hypertension in Europe Trial
(SYST-EUR),12 and 11 mm Hg below the Captopril Pre-
vention Project (CAPP) study.13 The 30 months results in
VALUE are a few millimeters lower compared to final
results of the Systolic Hypertension in Elderly Patients
(SHEP) study14 and Hypertension Optimal Treatment
(HOT)15 studies. The final average SBP in the recently
published Losartan Intervention For Endpoint reduction
(LIFE) study16 was 6 mm Hg higher in the losartan and 7.3
mm Hg higher in the atenolol group than the average SBP
achieved at the 30-month point in the VALUE study. Our
average SBP results at 30 months are similar to values
reported at the end of the Intervention as a Goal in Hy-
pertension Treatment (INSIGHT) study.17
Admittedly all of the studies quoted had a washout period
previous to the entry into the study, whereas in VALUE most
patients were “rolled over” from active treatment to our study
protocol. This makes it difficult to compare our entry BP
values to entry BP readings in other studies. However, we
can compare our results to the Anti-hypertensive and Lipid-
lowering Treatment to Prevent Heart Attack Trial (ALL-
HAT) study, which also used the rollover method. When the
data in the ALLHAT study18 average SBP are compared to
the VALUE results at a similar time point (2 years in both
studies), the achieved BP in the ALLHAT is lower than in
VALUE. The VALUE SBP at 2 years was 139 mm Hg
compared to 135.9, 137.1, and 138.4 mm Hg in the chlortha-
lidone, amlodipine, and lisinopril ALLHAT groups, respec-
tively. However, this comparison might not be appropriate as
the baseline SBP in ALLHAT (146.2 mm Hg) was substan-
tially lower than in the VALUE study (155.2 mm Hg). In
fact, in the ALLHAT chlorthalidone group, which achieved
the lowest in-treatment SBP, the decrease from the baseline
was 10.3 mm Hg compared to a 16 mm Hg SBP decrease in
the VALUE study.
Whereas all papers report on achieved BP levels in their
FIG. 5. Drug utilization and blood pressure control at 24 months in
the Valsartan Antihypertensive Long-term Use Evaluation study (N
 13,449). The numbers in bold are the percentages of all patients
at various drug (Rx.) steps. The numbers in italics describe the
percentage of patients whose blood pressure was controlled (140
and 90 mm Hg) within each category.
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study, only few discuss the results in terms of BP control
rates. At the end of the LIFE study,16 a 48% SBP control rate
(140 mm Hg) was reported, whereas defined more strictly
(140 mm Hg) the control rate in VALUE was 62.2% at 30
months. This is of particular interest because LIFE is the first
trial to use an angiotensin receptor blocking agent for control
of the BP in a long-term outcome trial in hypertension. The
ALLHAT study reported after 2 years of treatment a control
rate (140 and90 mm Hg) of 61%, 57.4%, and 54.1% for
chlorthalidon, amlodipine, and lisinopril, respectively. At the
same time point the control rate in VALUE was 57.6%.
In national surveys7 about 75% of treated hypertensive
subjects remain on monotherapy, even in the face of poor
control, predominantly with respect to SBP. It is encouraging
to see (Fig. 5) that at 24 months our physicians retained a
smaller proportion of patients on monotherapy (39.7%) com-
pared to 66% reported in national surveys.7 Among 5342
patients who at 24 months still received monotherapy, 70.5%
had adequate BP control (140 and 90 mm Hg.). How-
ever, almost 30% continued to receive monotherapy in spite
of inadequate BP control (140 and 90 mm Hg.) Among
these patients 27.9% had uncontrolled SBP and only 6.5%
had not achieved the DBP goal. In some of these patients the
physicians might have exercised proper clinical judgment but
we argue that more VALUE patients could be up-titrated to
diuretics. Clinical trials15 underscore the need for combina-
tion therapy to achieve rigorous BP targets and the VALUE
protocol called for addition of diuretics in such cases. Nev-
ertheless, the physicians in our study took that directive more
seriously with regard to DBP than SBP control. Surely in the
VALUE study there are some subjects whose SBP is genu-
inely resistant to treatment. For example, among patients who
received “add-on” therapy on top of full dose of treatment
drugs and diuretics (step 5), the BP was too high in 61.3%.
Nevertheless, the true proportion and the clinical character-
istics of patients whose SBP is resistant to treatment will be
known only after all therapeutic options for controlling BP
provided by the VALUE protocol have been fully used.
The results presented demonstrate that organizational
and educational efforts to improve the SBP control can be
efficacious. Our BP-lowering initiative has been well re-
ceived by the study physicians and BP in the study con-
tinues decreasing. We believe that setting a fixed stepwise
algorithm of drug usage was an important component in
the improvement of BP control in the VALUE study.
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